The Vacaville facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics manufacturing sites worldwide by volume, Lonza said. "The ...

Lonza shares rise 6.7% after CHI exit announcement ... CDMO will be restructured into three business platforms - Integrated Biologics, Advanced Synthesis and Specialized Modalities - from the ...

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

A $1.2 billion deal by Swiss biotech firm Lonza to purchase the Vacaville Genentech ... “As the Vacaville site joins our Biologics division, we look forward to bringing new customer projects ...

With the purchase of a former Lonza biologics plant now in the books, San Francisco-based CDMO Joinn Biologics is expanding from one Bay Area to another. Over the weekend, Joinn announced (Chinese ...

Lonza also revealed at the event that it will streamline its CDMO businesses into three platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. The Integrated Biologics ...

Lonza Biologics and Vertex Pharmaceuticals, with the help of local officials, broke ground Aug. 30 on the construction of a 130,000-square-foot facility at Pease International Tradeport in Portsmouth.